Located in Hørsholm, near Copenhagen, Roche Innovation Center Copenhagen (RICC) employs approximately 70 employees. RICC originates from the Danish biotech company Santaris Pharma A/S that was acquired by Roche in August 2014. Roche’s Innovation Center in Copenhagen is a leader in the field of Nucleic Acid-Based Medicines focusing on Ribonucleic acid (RNA) targeting drugs. The deep understanding of RNA mechanisms and how to modulate them enables the discovery of important novel medicines across multiple therapeutic areas in pRED.
Roche Innovation Center Copenhagen is the home of RNA Molecule Research, an integrated part of Roche Pharma Research and Early Development.
The Roche Innovation Center in Copenhagen, originating from the acquisition of Santaris Pharma in 2014, is a leader in the rapidly emerging field of RNA-targeted drugs. It is developing important novel medicines across multiple therapeutic areas.
The deep understanding of RNA mechanisms and how to modulate them enables discovery of important novel medicines across multiple therapeutic areas. At the same time, this novel class of drugs offers the means to address disease targets that have previously been undruggable with conventional drug therapies such as small molecules or antibodies. RICC is continuously investing in its drug discovery and technology platform bringing together a multidisciplinary team of scientists with experience, talent, and commitment to deliver on the promise of RNA medicines. The RICC team comprises research specialists in oligonucleotide and conjugate chemistry, molecular biology, cell biology, pharmacokinetics, and bioinformatics.
Recognizing the broad application of RNA medicines, RICC is collaborating with selected pharmaceutical companies to discover and develop novel Nucleic Acid-Based Medicines within their therapeutic focus areas. These efforts complement other drug discovery efforts within the Roche Group and accelerate the emergence of the new RNA-therapeutic era in human medicine.